Discontinued — last reported Q3 '24
Business Segments · Goodwill
Diagnostics and Genomics — Goodwill
Agilent Technologies Diagnostics and Genomics — Goodwill increased by 24.1% to $2.64B in Q3 2024 compared to the prior quarter. Year-over-year, this metric grew by 24.1%, from $2.12B to $2.64B. Over 3 years (FY 2021 to FY 2024), Diagnostics and Genomics — Goodwill shows an upward trend with a 6.0% CAGR.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ3 2014
Last reportedQ3 2024
Rolls up toGoodwill
How to read this metric
A stable or growing balance suggests ongoing acquisition activity, while a sudden decrease may signal impairment testing results.
Detailed definition
This represents the excess of the purchase price over the fair value of identifiable net assets acquired in business com...
Peer comparison
Standard balance sheet item for companies that grow through inorganic expansion in the life sciences sector.
Metric ID:
a_segment_diagnostics_and_genomics_goodwillHistorical Data
15 periods
| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.04B | $1.97B | $1.96B | $1.96B | $1.96B | $1.95B | $1.95B | $1.97B | $1.97B | $1.97B | $2.12B | $2.12B | $2.12B | $2.12B | $2.64B |
| QoQ Change | — | -3.5% | -0.1% | -0.2% | -0.2% | -0.2% | -0.1% | +0.6% | +0.3% | -0.1% | +7.9% | +0.0% | +0.0% | +0.0% | +24.1% |
| YoY Change | — | — | — | — | -3.9% | -0.6% | -0.6% | +0.2% | +0.7% | +0.8% | +8.8% | +8.1% | +7.8% | +7.9% | +24.1% |
Range$1.95B – $2.64B
CAGR+7.6%
Avg YoY Growth+4.8%
Median YoY Growth+0.8%
Current Streak5 quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Agilent Technologies's diagnostics and genomics — goodwill?
- Agilent Technologies (A) reported diagnostics and genomics — goodwill of $2.64B in Q3 2024.
- How has Agilent Technologies's diagnostics and genomics — goodwill changed year-over-year?
- Agilent Technologies's diagnostics and genomics — goodwill increased by 24.1% year-over-year, from $2.12B to $2.64B.
- What is the long-term trend for Agilent Technologies's diagnostics and genomics — goodwill?
- Over 3 years (2021 to 2024), Agilent Technologies's diagnostics and genomics — goodwill has grown at a 6.0% compound annual growth rate (CAGR), from $7.57B to $9.01B.
- What does diagnostics and genomics — goodwill mean?
- The intangible asset value representing the premium paid for past acquisitions in this segment.